FDA Grants De Novo Classification to Neuropacs, Establishing New Category in Parkinsonian Diagnostics

A signal just moved through neurological imaging that does not ask for attention but earns it. Neuropacs Corp., based in Gainesville, Florida, announced that the U.S. Food and Drug Administration granted De Novo classification to neuropacs, a diffusion MRI-based software application built to assist clinicians evaluating Parkinsonian syndromes. Not noise, not hype, just a measured step into one of medicine’s more complex diagnostic arenas.

Neuropacs is stepping into a problem that does not announce itself cleanly. Parkinson’s disease, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy can present with overlapping symptoms, especially early, where clinical judgment is forced to operate with incomplete clarity. Neuropacs leans into that uncertainty, not by claiming certainty, but by structuring it. The software analyzes diffusion MRI data and generates a classification report based on degenerative brain patterns tied to MSAp and PSP, offering supplemental insight to help differentiate them from Parkinson’s disease within a broader clinical assessment.

The FDA did more than clear a product. It defined a category. Parkinsonian syndrome diagnostic aid now exists as a formal lane, and neuropacs is the first device classified within it. That matters because categories shape behavior. Hospitals, clinicians, procurement teams, they move faster when the path is labeled. Neuropacs is no longer asking where it fits. It has a place to stand.

The foundation under that moment is not thin. The technology draws from more than 15 years of research and over 1,000 imaging datasets, with clinical validation anchored in a prospective multicenter study published in JAMA Neurology, supported by the National Institutes of Health and conducted across 21 movement disorder centers in the Parkinson Study Group.

Dr. Martin Handfield, President and Chief Executive Officer of Neuropacs, put it plainly, noting that the classification establishes a new regulatory category and enables broader access to tools that may support clinicians assessing Parkinsonian syndromes. Around him sits a team built for this transition. Dr. David Vaillancourt, Co-founder and Chief Scientific Officer, brings the research backbone. Dr. Angelos Barmpoutis, Founder and Chief Technology Officer and Chief Information Security Officer, carries the technical architecture. Dwight L. Hulse oversees finance, with Rick Staab and Jackson Streeter on the board as the company moves from controlled research into real-world deployment.

The product itself stays grounded. Neuropacs runs on standard diffusion MRI sequences across 3 Tesla systems from Siemens, GE Healthcare, and Philips, using a free-water imaging model and machine learning algorithm delivered through a cloud-based workflow. One scan, non-invasive, no radiotracers. A classification report that informs, not dictates. The company is explicit that it is not a standalone diagnostic, and that restraint is part of the credibility.

Timing adds pressure in the right direction. The FDA decision follows a recently announced seed round of over one million dollars, positioned to move Neuropacs from research into commercialization while expanding clinical and trial-support capabilities. Capital meets clearance, and now the question shifts from can it work to where it lands first.

Neuropacs sounds like a name built for packaging complexity, and that is exactly the game. The brain does not simplify itself, but the tools around it are starting to get sharper, more structured, more usable. Now that the category exists and the door is open, the next move is not theoretical, it is clinical, and the room is already watching.